These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16359511)

  • 21. The inflammatory-coagulant axis in the host response to gram-negative sepsis: regulatory roles of proteins and inhibitors of tissue factor.
    Taylor FB
    New Horiz; 1994 Nov; 2(4):555-65. PubMed ID: 7804804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. TAFI deficiency causes maladaptive vascular remodeling after hemophilic joint bleeding.
    Wyseure T; Yang T; Zhou JY; Cooke EJ; Wanko B; Olmer M; Agashe R; Morodomi Y; Behrendt N; Lotz M; Morser J; von Drygalski A; Mosnier LO
    JCI Insight; 2019 Oct; 4(19):. PubMed ID: 31465300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factor XIII cotreatment with hemostatic agents in hemophilia A increases fibrin α-chain crosslinking.
    Beckman JD; Holle LA; Wolberg AS
    J Thromb Haemost; 2018 Jan; 16(1):131-141. PubMed ID: 29080382
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor.
    Waters EK; Genga RM; Schwartz MC; Nelson JA; Schaub RG; Olson KA; Kurz JC; McGinness KE
    Blood; 2011 May; 117(20):5514-22. PubMed ID: 21389323
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of extrinsic pathway inhibitor shortens the coagulation time of normal plasma and of hemophilia plasma.
    Nordfang O; Valentin S; Beck TC; Hedner U
    Thromb Haemost; 1991 Oct; 66(4):464-7. PubMed ID: 1796397
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombin generation and phenotypic correlation in haemophilia A.
    Beltrán-Miranda CP; Khan A; Jaloma-Cruz AR; Laffan MA
    Haemophilia; 2005 Jul; 11(4):326-34. PubMed ID: 16011583
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice.
    VandenDriessche T; Vanslembrouck V; Goovaerts I; Zwinnen H; Vanderhaeghen ML; Collen D; Chuah MK
    Proc Natl Acad Sci U S A; 1999 Aug; 96(18):10379-84. PubMed ID: 10468616
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The mesenchymal stem cells derived from transgenic mice carrying human coagulation factor VIII can correct phenotype in hemophilia A mice.
    Wang Q; Gong X; Gong Z; Ren X; Ren Z; Huang S; Zeng Y
    J Genet Genomics; 2013 Dec; 40(12):617-28. PubMed ID: 24377868
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phenotypic correction and long-term expression of factor VIII in hemophilic mice by immunotolerization and nonviral gene transfer using the Sleeping Beauty transposon system.
    Ohlfest JR; Frandsen JL; Fritz S; Lobitz PD; Perkinson SG; Clark KJ; Nelsestuen G; Key NS; McIvor RS; Hackett PB; Largaespada DA
    Blood; 2005 Apr; 105(7):2691-8. PubMed ID: 15576475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Binding of Factor VIII to Lipid Nanodiscs Increases its Clotting Function in a Mouse Model of Hemophilia A.
    Csencsits-Smith K; Grushin K; Stoilova-McPhie S
    J Blood Disord Transfus; 2015 Dec; 6(6):325. PubMed ID: 28936365
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Granulocyte-macrophage-colony-stimulating factor-dependent peritoneal macrophage responses determine survival in experimentally induced peritonitis and sepsis in mice.
    Spight D; Trapnell B; Zhao B; Berclaz P; Shanley TP
    Shock; 2008 Oct; 30(4):434-42. PubMed ID: 18277945
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A major determinant of the immunogenicity of factor VIII in a murine model is independent of its procoagulant function.
    Meeks SL; Cox CL; Healey JF; Parker ET; Doshi BS; Gangadharan B; Barrow RT; Lollar P
    Blood; 2012 Sep; 120(12):2512-20. PubMed ID: 22855607
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Type I IFN modulates host defense and late hyperinflammation in septic peritonitis.
    Weighardt H; Kaiser-Moore S; Schlautkötter S; Rossmann-Bloeck T; Schleicher U; Bogdan C; Holzmann B
    J Immunol; 2006 Oct; 177(8):5623-30. PubMed ID: 17015750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. EPCR deficiency or function-blocking antibody protects against joint bleeding-induced pathology in hemophilia mice.
    Magisetty J; Pendurthi UR; Esmon CT; Rao LVM
    Blood; 2020 Jun; 135(25):2211-2223. PubMed ID: 32294155
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hemophilia A--from basic science to clinical practice.
    Klinge J; Ananyeva NM; Hauser CA; Saenko EL
    Semin Thromb Hemost; 2002 Jun; 28(3):309-22. PubMed ID: 12098093
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In Vitro FVIII-Encoding Transgenic Mesenchymal Stem Cells Maintain Successful Coagulation in FVIII-Deficient Plasma Mimicking Hemophilia A.
    Hemşinlioğlu C; Aslan ES; Taştan C; Çakırsoy D; Turan RD; Seyis U; Elek M; Sır Karakuş G; Günaydın ÖS; Abanuz S; Kançağı DD; Yurtsever B; Yalçın K; Kasap M; Ovalı E
    Turk J Haematol; 2023 May; 40(2):118-124. PubMed ID: 37022209
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The disappearing act of factor VIII.
    Lenting PJ; Christophe OD; Guéguen P
    Haemophilia; 2010 May; 16(102):6-15. PubMed ID: 18771423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heterozygous antithrombin deficiency improves in vivo haemostasis in factor VIII-deficient mice.
    Bolliger D; Szlam F; Suzuki N; Matsushita T; Tanaka KA
    Thromb Haemost; 2010 Jun; 103(6):1233-8. PubMed ID: 20352163
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis.
    van Westerloo DJ; Giebelen IA; Florquin S; Daalhuisen J; Bruno MJ; de Vos AF; Tracey KJ; van der Poll T
    J Infect Dis; 2005 Jun; 191(12):2138-48. PubMed ID: 15898001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Routine measurements of factor VIII activity and inhibitor titer in the presence of emicizumab utilizing anti-idiotype monoclonal antibodies.
    Nogami K; Soeda T; Matsumoto T; Kawabe Y; Kitazawa T; Shima M
    J Thromb Haemost; 2018 Jul; 16(7):1383-1390. PubMed ID: 29734520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.